Radiopharmaceuticals
Radiopharmaceuticals are rapidly redefining oncology by enabling precise, tumor-targeted isotope delivery, with over 80 potential therapies currently in clinical development and a growing demand for specialized preclinical support.
As a preclinical CRO with 15+ years of experience supporting complex R&D programs for a wide array of startup, biotech and large pharmaceutical companies, Powered Research meets this demand with a fully integrated, single-site platform under one roof.
By unifying in vivo tumor biology, radioactive compound administration, and downstream analytics within the same facility and scientific team, we eliminate the inefficiencies of multi-vendor CRO models. No separate SOWs, no transport of radioactive materials and no fragmented datasets.
Our non-GLP services support radiopharmaceutical drug development, including targeted radioligands and next-generation radiotherapeutics across alpha- and beta-emitting isotopes. We leverage advanced rodent tumor models to evaluate biodistribution, PK/PD, dosimetry, and therapeutic efficacy, generating high-resolution datasets that directly inform translational strategy.
Capabilities
-
Traditional human tumor xenograft and syngeneic models
-
Advanced mouse and rat tumor models (subcutaneous, orthotopic, metastatic, CDX and PDX)
-
Surgical and orthotopic implantation of human and murine tumor cell lines
-
Evaluation of radiopharmaceutical therapies (dosing, sampling, and analyses)
-
Spectral flow cytometry for deep immunophenotyping (>18-color panels)
-
Cytokine profiling (serum, plasma, tumor lysates)
-
On-site tissue processing (FFPE and cryosectioning)
-
Comprehensive histology: IHC, IF, H&E, ISH
-
Epifluorescence microscopy and custom image analysis pipelines
Integrated Data, Delivered Faster
Eliminate fragmentation. Accelerate your radiopharmaceutical program.
Contact Powered Research to design a biodistribution, PK/PD and efficacy study in mouse and rat tumor models, executed end-to-end under one roof.